Aspirin resistance in patients with acute coronary syndrome. Part 1

Aim. To evaluate the prevalence of aspirin resistance, its clinical features, potential solutions, and prognostic role in patients with acute coronary syndrome (ACS). Material and methods. The study included 51 patients with ACS and ST segment elevation (STEACS) and 49 ACS patients without ST segment elevation (non-STEACS). All participants received aspirin in a standard dose of 100 mg/d. Platelet aggregation (PA) was measured with a laser assay method and arachidonic acid (0,5 mg/dl) as an inductor. Aspirin resistance was diagnosed if PA was at least 20% at Day 7 of aspirin treatment. Results. Aspirin resistance was observed in 11% of the patients receiving aspirin in a standard dose of 100 mg/d. The majority of aspirin-resistant patients had STEACS, therefore, the data for this group were analysed in detail. Major clinical characteristics of aspirin-resistant and aspirin-responding patients were similar. After the in vitro test with aspirin, to determine the pharmacokinetic type of aspirin resistance, the medication dose was increased to 300 mg/d. The comparison group included 10 patients with STEACS, receiving aspirin in the dose of 100 mg/d. Thirty days later, PA was significantly reduced in both aspirin-resistant groups, therefore, the aspirin dose increase did not affect PA dynamics. In aspirin-resistant patients, prognosis was slightly worse than in their aspirinresponding peers. Conclusion. Aspirin resistance was more prevalent in STEACS patients. By Day 30, PA was substantially reduced. Increasing aspirin dose to 300 mg/d did not affect PA dynamics.

1. Awtry EH, Lescalzo J. Aspirin. Circulation 2000; 101: 1206-18.

2. Patrono C. Aspirin resistance: definition, mechanisms and clinical readouts. Thromb Haemost. 2003; 1: 1710 - 3.

3. Hankey GL, Eikelboom J. Aspirin resistance. Lancet 2006; 367: 606-17.

4. Hennekens CH, Shlor K, Weisman S, et al. Terms and conditions. Semantic complexity and aspirin resistance. Circulation 2004; 110: 1706-8.

5. Halushka MR, Halushka PV. Why are some individuals resistant to the cardioprotective effect of aspirin? Could it be thromboxan A2? Circulation 2002; 105: 1620-2.

6. Weber AA, Przytulski B, Schanz A, et al. Towards definition of aspirin resistance: a typologycal approach. Platelets 2002; 13: 37-40.

7. Diagnostika i lechenie bol'nykh s ostrym infarktom miokarda s pod"emom segmenta ST elektrokardiogrammy. Rossiiskie rekomendatsii Komiteta ekspertov VNOK.

8. Gum PA, Kottke-Marchant K, Poggio ED, et al. Prospective, blinded detremination of the natural history of th aspirin resistance among stable patients with cardiovascular disease. JACC 2003; 41: 961-5.

9. Tarjan J, Salamon A, Jager R, et al. The rate of ASA non - responders among patients hospitalized for acute coronary disease, previously undergoing secondary ASA prophilaxis. Orv Hetil.1999; 240 (42): 2334-43.

10. Chen W-H, Lee P-Y, William Ng, et al. Aspirin resistance is associated with high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. JACC 2004; 43: 1122-6.

11. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647-54.

12. Hung J, Lam JY, Lacoste L, et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-6.

13. DiMinno, Silver MJ, Cerbone AM, et al. Trial of repeated low dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-91.

14. Watala C, Pelligrini F, Pluta J, et al. Reduced sensitivity of platelets from diabetes mellitus type 2 to aspirin - its relation to metabolic control. Thromb Res 2004; 113: 101-13.

15. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evolution of platelet aspirin resistance after coronary bypass surgery. Circulation 2003; 108: 542-7.

16. Wong S, Appelberg M, Ward C, et al. Aspirin resistance in cardiovascular disease: A review. Eur O Vasc Endovasc Surg 2003; 27: 456-65.

17. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspririn resistance in persons with previous stroke. Stroke 1994; 25: 2331-6.

18. Andersen K, Hurlen M, Arnesen H, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Research 2002; 108: 37-42.

19. Grotemeyer KH, Scharafinski HW, Husstadt IW. Two - year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 78: 1003-7.

20. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and risc of limd deterioration in patients submitted to peripheral artery angioplasty. Thromb Haemost 1997; 78: 1003-7.